ChiCTR-ONRC-12002840 版本V1.2 版本创建时间2015/12/27 21:46:38 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR-ONRC-12002840 

最近更新日期:

Date of Last Refreshed on:

2015-12-27 21:43:26 

注册时间:

Date of Registration:

2012-12-10 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

保留子宫盆底重建术和盆底重建术合并子宫切除的临床对照研究

Public title:

Comparison of the clinical efficacy of pelvic reconstruction with transvaginal mesh for pelvic organ prolapse repair: hysterectomy or not?

注册题目简写:

English Acronym:

研究课题的正式科学名称:

保留子宫盆底重建术和盆底重建术合并子宫切除的临床对照研究

Scientific title:

Comparison of the clinical efficacy of pelvic reconstruction with transvaginal mesh for pelvic organ prolapse repair: hysterectomy or not?

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

周全 

研究负责人:

宋岩峰 

Applicant:

Zhou Quan 

Study leader:

Song Yanfeng 

申请注册联系人电话:

Applicant telephone:

+86 18259060476

研究负责人电话:

Study leader's
telephone:

+86 13905909403

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

zhouquan8519@163.com

研究负责人电子邮件:

Study leader's E-mail:

zlele@126.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

福建省福州市西二环北路156号福州总院妇产科

研究负责人通讯地址:

福建省福州市西二环北路156号福州总院妇产科

Applicant address:

156 North Second Ring Road, Fuzhou, Fujian, China

Study leader's address:

156 North Secondary Ring Road, Gulou District, Fuzhou, Fujian, China

申请注册联系人邮政编码:

Applicant postcode:

350025

研究负责人邮政编码:

Study leader's postcode:

350025

申请人所在单位:

南京军区福州总医院妇产科

Applicant's institution:

Department of Obstetrics & Gynecology, Fuzhou General Hospital Nanjing Military Region

研究负责人所在单位:

Affiliation of the Leader:

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2012269

伦理委员会批件附件:

Approved file of Ethical Committee:

批准本研究的伦理委员会名称:

南京军区福州总医院伦理委员会

Name of the ethic committee:

The Ethics Committee of Fuzhou General Hospital of Nanjing Military Region

伦理委员会批准日期:

Date of approved by ethic committee:

2013-08-26 00:00:00

伦理委员会联系人:

Contact Name of the ethic committee:

伦理委员会联系地址:

Contact Address of the ethic committee:

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

南京军区福州总医院

Primary sponsor:

Fuzhou General Hospital Nanjing Military Region

研究实施负责(组长)单位地址:

福建省福州市西二环北路156号福州总医院妇产科

Primary sponsor's address:

156 North Secondary Ring Road, Gulou District, Fuzhou, Fujian, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

经费或物资来源:

国家科技支持计划

Source(s) of funding:

National Science and Technology Support Program

研究疾病:

盆腔器官脱垂  

Target disease:

pelvic organ prolapse

研究疾病代码:

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

IV期临床试验 

Study phase:

4

研究设计:

非随机对照试验 

Study design:

Non randomized control 

研究目的:

评估保留子宫盆底重建术的临床疗效及安全性,并观察其对生活质量的影响  

Objectives of Study:

To Compare the clinical efficacy, safety and the quality of life of pelvic reconstruction with transvaginal mesh for pelvic organ prolapse repair: hysterectomy or not?

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

所有应用网片进行盆腔器官脱垂修复的患者

Inclusion criteria

All patients who underwent surgery with the synthetic mesh

排除标准:

不签订知情同意书的患者

Exclusion criteria:

Unable to give informed consent to participate

研究实施时间:

Study execute time:

From 2012-06-06 00:00:00 To 2014-09-21 00:00:00  

征募观察对象时间:

Recruiting time:

From 2012-06-06 00:00:00 To 2014-09-21 00:00:00

干预措施:

Interventions:

组别:

子宫切除组

样本量:

50

Group:

hysterectomy

Sample size:

干预措施:

盆底重建+阴式子宫切除术

干预措施代码:

Intervention:

transvaginal pelvic reconstruction+hysterectomy

Intervention code:

组别:

保留子宫组

样本量:

50

Group:

uterine preservation

Sample size:

干预措施:

盆底重建术

干预措施代码:

Intervention:

transvaginal pelvic reconstruction

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

福建 

市(区县):

 

Country:

China

Province:

Fujian

City:

单位(医院):

南京军区福州总医院 

单位级别:

三级甲等 

Institution
hospital:

Fuzhou General Hospital Nanjing Military Region

Level of the institution:

Tertiary A hospital

国家:

中国

省(直辖市):

辽宁 

市(区县):

 

Country:

China

Province:

Liaoning

City:

单位(医院):

中国医科大学附属盛京医院 

单位级别:

三级甲等 

Institution
hospital:

Affiliated Shengjing Hospital of China Medical University

Level of the institution:

Tertiary A hospital

国家:

中国

省(直辖市):

浙江 

市(区县):

 

Country:

China

Province:

Zhejiang

City:

单位(医院):

浙江大学附属医院附属妇产医院 

单位级别:

三级甲等 

Institution
hospital:

Women's Hospital School of Medicine Zhejiang University

Level of the institution:

Tertiary A hospital

国家:

中国

省(直辖市):

上海 

市(区县):

 

Country:

China

Province:

Shanghai

City:

单位(医院):

上海交通大学附属第六人民医院 

单位级别:

三级甲等 

Institution
hospital:

Shanghai Sixth People’s Hospital Affiliated to Shanghai Jiao Tong University

Level of the institution:

Tertiary A hospital

测量指标:

Outcomes:

指标中文名:

客观治愈率

指标类型:

主要指标

Outcome:

Anatomical improvement according to POP-Q score

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

客观失败率

指标类型:

主要指标

Outcome:

Anatomical no provement according to POP-Q score

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

并发症

指标类型:

主要指标

Outcome:

Presence/absence of complication

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

生活质量1

指标类型:

次要指标

Outcome:

the Pelvic Floor Distress Inventory (PFDI-20)

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

生活质量2

指标类型:

次要指标

Outcome:

The Pelvic Floor Impact Questionnaire (PFIQ-7)

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

性生活质量

指标类型:

次要指标

Outcome:

Pelvic Organ Prolapse/Urinary Incontinence Sexual

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 99 years

性别:

男性

Gender:

Male

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

数据与安全监察委员会:

Data and Safety Monitoring Committee:

注册人:

Name of Registration:

 2012-12-21 00:00:00